Finding the Optimal Dose of Regorafenib in Colorectal Cancer
John H. Strickler, MD, discusses dosing of regorafenib in patients with colorectal cancer.
John H. Strickler, MD, medical oncologist, Duke Cancer Center, Duke Health, discusses dosing of regorafenib (Stivarga) in colorectal cancer.
Treatment with regorafenib in patients with colorectal cancer often involves dose escalations. The purpose for escalating the dose of this drug is to ensure that patients receive a dose that provides the best quality of life.
Efficacy is typically not sacrificed when patients are given a lower dose of regorafenib and are gradually escalated to a higher dose, says Strickler. In addition, there is no data to suggest that a higher dose of regorafenib improves efficacy. Strickler recommends focusing on the tolerability of the agent when deciding on escalation or even de-escalation, if needed.
Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback
July 18th 2024Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.
Read More
